In real-world practice, oncologists are granting treatment breaks, or 'holidays,' to metastatic bladder cancer patients who achieve major responses on enfortumab vedotin-pembrolizumab. This practice, driven by toxicity management and quality of life concerns, is common despite the lack of formal trial data to guide the optimal duration or timing of discontinuation.

For the typically young and active desmoid tumor patient population, the convenience of a once-daily oral pill is a major advantage. This seemingly simple feature significantly improves compliance and adherence compared to twice-daily regimens, making it a key factor in real-world treatment feasibility and success, more so than the specific milligram dosage.

TAMP is delivered once every two weeks, but crucially, patients generally do not receive other treatments concurrently. This regimen provides significant breaks from therapy, helping to preserve pre-procedural quality of life—a major advantage over the continuous burden of systemic chemotherapy.

New targeted therapies like Zanidatamab and Zolbetuximab show great promise but cause significant side effects like diarrhea and nausea. Their successful clinical adoption hinges on proactive management using detailed guidelines and prophylactic medications, as toxicity can be severe enough to force treatment discontinuation despite the drug's efficacy.

The Phase 2 TRAIT study suggests starting adjuvant abemaciclib at a lower dose and escalating over several weeks significantly reduces early discontinuations due to side effects like diarrhea. This strategy helps more patients get through the initial high-toxicity period and remain on the effective dose for the full two-year course.

A trial investigating intermittent versus continuous axitinib in metastatic RCC addresses a major clinical challenge: the significant toxicity and impaired quality of life from continuous TKI therapy. Proving non-inferiority for an intermittent schedule could fundamentally change patient management and improve long-term tolerability.

The side effect profile of capivasertib is front-loaded. Key toxicities like diarrhea and rash appear quickly, leading to the majority (63%) of drug discontinuations occurring within the first three months. This highlights a critical window for proactive management and patient education to improve adherence.

To mitigate long-term toxicity from TDXD, oncologists are proposing an "induction/maintenance" approach. Patients receive TDXD for an initial period to achieve maximal response, then switch to a less toxic maintenance regimen for a "chemotherapy holiday," improving quality of life.

Clinicians must counsel patients that some drug toxicities are irreversible or create lifelong conditions. Alopecia from hedgehog inhibitors can be permanent, while immunotherapy-induced adrenal insufficiency or Type 1 diabetes require daily management, a significant quality-of-life burden for older patients.